# TUMOR-ASSOCIATED MACROPHAGES

# STRATEGIC REVIEW 2018



## Contents

Executive summary

Key findings

- 1.0 Background & Defining the TAM population
- 2.0 Regulation of Macrophage activation
- 3.0 Defining TAM populations
- 4.0 Characterisation of TAMs by Pro-tumoral functions
- 5.0 Metabolic understanding of TAMs
- 6.0 Role of HDACs in TAM biology
- 7.0 Commercial Landscape
- 8.0 Literature highlights from 2017-2018
- 9.0 Concluding remarks

### List of Tables

- Table 1. Key macrophage polarisation markers
- Table 2. Marker sets used to identify TAMs
- Table 3. HDAC inhibitors (FDA approved or currently undergoing clinical trials in oncology)

#### List of Figures

- Figure 1. M1 Activation
- Figure 2. M2 Activation
- Figure 3. TAM crosstalk within the TME
- Figure 4. Metabolic differences during M1 and M2 activation
- Figure 5. Glycolysis and PPP during M1 and M2 activation
- Figure 6. CSF1R targeting agents
- Figure 7. CD40 targeting agents
- Figure 8. Tim-3 & PI3K targeting agents
- Figure 9. Novel experimental approaches identified in 2017/2018 literature search
- Figure 10. Word cloud based on 500 abstracts from TAMs papers 2017-2018